kleintier konkret 2017; 20(06): 18-27
DOI: 10.1055/s-0043-110397
hund
onkologie
Enke Verlag in Georg Thieme Verlag KG Stuttgart

Hauttumoren des Hundes

Julia Gedon
Tierklinik Hofheim
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2017 (online)

Beim Hund sind Hauttumoren ein häufiger Grund für eine Vorstellung beim Tierarzt. Ihre Malignität wird deutlich unterschätzt, denn immerhin verhalten sich etwa 20–30 % aller Hauttumoren beim Hund maligne [[19]]. Eine gute Diagnostik und eine adäquate Therapie sind daher essenziell für die weitere Prognose [[12]].

 
  • Literatur

  • 1 Baer KE, Patnaik AK, Gilbertson SR. et al. Cutaneous plasmacytomas in dogs: a morphologic and immunohistochemical study. Vet Pathol 1989; 26 (3): 216-221
  • 2 Baez JL, Hendrick MJ, Shofer FS. et al. Liposarcomas in dogs: 56 cases (1989–2000). J Am Vet Med Assoc 2004; 224 (6): 887-891
  • 3 Belluco S, Brisebard E, Watrelot D. et al. Digital squamous cell carcinoma in dogs: epidemiological, histological, and immunohistochemical study. Vet Pathol 2013; 50 (6): 1078-1082
  • 4 Fontaine J, Heimann M, Day MJ. Canine cutaneous epitheliotropic T-cell lymphoma: a review of 30 cases. Vet Dermatol 2010; 21 (3): 267-275
  • 5 Fontaine J, Bovens C, Bettenay S. et al. Canine cutaneous epitheliotropic T-cell lymphoma: a review. Vet Comp Oncol 2009; 7 (1): 1-14
  • 6 Fuerst JA, Reichle JK, Szabo D. et al. Computed tomographic findings in 24 dogs with liposarcoma. Vet Radiol Ultrasound 2017; 58 (1): 23-28
  • 7 Ghisleni G, Roccabianca P, Ceruti R. et al. Correlation between fine-needle aspiration cytology and histopathology in the evaluation of cutaneous and subcutaneous masses from dogs and cats. Vet Clin Pathol 2006; 35 (1): 24-30
  • 8 Graves GM, Bjorling DE, Mahaffey E. Canine hemangiopericytoma: 23 cases (1967–1984). J Am Vet Med Assoc 1988; 192 (1): 99-102
  • 9 Hahn KA, Ogilvie G, Rusk T. et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008; 22 (6): 1301-1309
  • 10 Hargis AM, Ihrke PJ, Spangler WL. et al. A retrospective clinicopathologic study of 212 dogs with cutaneous hemangiomas and hemangiosarcomas. Vet Pathol 1992; 29 (4): 316-328
  • 11 Kalaher KM, Anderson WI, Scott DW. Neoplasms of the apocrine sweat glands in 44 dogs and 10 cats. Vet Rec 1990; 127 (16): 400-403
  • 12 Kessler M. Kleintieronkologie. 3. Aufl. Stuttgart: Enke; 2013
  • 13 Klopfleisch R, Sperling C, Kershaw O. et al. Does the taking of biopsies affect the metastatic potential of tumours? A syste-matic review of reports on veterinary and human cases and animal models. Vet J 2011; 190 (2): e31-42
  • 14 Knapp DW, Richardson RC, Bottoms GD. et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992; 29 (3): 214-218
  • 15 Leidinger EF, Freeman K, Kirtz G. et al. Breed related odds ratio and anatomic distribution of canine mast cell tumours in Austria. Retrospective study of cases in the years 2000–2010 Tierarztl Prax Ausg K Kleintiere Heimtiere 2014; 42 (6): 367-373
  • 16 Mineshige T, Kawarai S, Yauchi T. et al. Cutaneous epitheliotropic T-cell lymphoma with systemic dissemination in a dog. J Vet Diagn Invest 2016; 28 (3): 327-331
  • 17 Murphy S, Sparkes AH, Smith KC. et al. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec 2004; 154 (24): 743-746
  • 18 Nicholls PK, Moore PF, Anderson DM. et al. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001; 283 (1): 31-39
  • 19 Pakhrin B, Kang MS, Bae IH. et al. Retrospective study of canine cutaneous tumors in Korea. J Vet Sci 2007; 8 (3): 229-236
  • 20 Pestili de Almeida EM, Piché C, Sirois J. et al. Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 2001; 49 (7): 867-875
  • 21 Pires I, Alves A, Queiroga FL. et al. Regression of canine cutaneous histiocytoma: reduced proliferation or increased apoptosis?. Anticancer Res 2013; 33 (4): 1397-1400
  • 22 Plavec T, Kessler M, Kandel B. et al. Palliative radiotherapy as treatment for non-resectable soft tissue sarcomas in the dog – a report of 15 cases. Vet Comp Oncol 2006; 4 (2): 98-103
  • 23 Puff C, Risha E, Baumgärtner W. Regression of canine cutaneous histiocytoma is associated with an orchestrated expression of matrix metalloproteinases. J Comp Pathol 2013; 149 (2–3): 208-215
  • 24 Rakich PM, Latimer KS, Weiss R. et al. Mucocutaneous plasmacytomas in dogs: 75 cases (1980–1987). J Am Vet Med Assoc 1989; 194 (6): 803-810
  • 25 Rassnick KM, Russlander DM, Cotter SM. et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989–2000). J Am Vet Med Assoc 2001; 218 (9): 1444-1448
  • 26 Richman AW, Kirby AL, Rosenkrantz W. et al. Persistent papilloma treated with cryotherapy in three dogs. Vet Dermatol 2017; DOI: 10.1111/vde.12469.
  • 27 Risbon RE, de Lorimier LP, Skorupski K. et al. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retro-spective study of 46 cases (1999–2004). J Vet Intern Med 2006; 20 (6): 1389-1397
  • 28 Rout ED, Shank AM, Waite AH. et al. Progression of cutaneous plasmacytoma to plasma cell leukemia in a dog. Vet Clin Pathol 2017; 46 (1): 77-84
  • 29 Sabattini S, Scarpa F, Berlato D. et al. Histologic grading of canine mast cell tumor: is 2 better than 3?. Vet Pathol 2015; 52 (1): 70-73
  • 30 Sancak A, Favrot C, Geisseler MD. et al. Antibody titres against canine papillomavirus 1 peak around clinical regression in naturally occurring oral papillomatosis. Vet Dermatol 2015; 26 (1): 57-59 e19–20
  • 31 Schultheiss PC. Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed locations of dogs. J Vet Diagn Invest 2006; 18 (4): 422-425
  • 32 Schultheiss PC. A retrospective study of visceral and nonvisceral hemangiosarcoma and hemangiomas in domestic animals. J Vet Diagn Invest 2004; 16 (6): 522-526
  • 33 Scott DW, Anderson WI. Canine sebaceous gland tumors: a retrospective analysis of 172 cases. Canine Practice 1990; 15 (1): 19-21
  • 34 Shoop SJ, Marlow S, Church DB. et al. Prevalence and risk factors for mast cell tumours in dogs in England. Canine Genet Epidemiol 2015; 2: 1
  • 35 Simko E, Wilcock BP, Yager JA. A retrospective study of 44 canine apocrine sweat gland adenocarcinomas. Can Vet J 2003; 44 (1): 38-42
  • 36 Stockhaus C, Teske E, Rudolph R. et al. Assessment of cytological criteria for diagnosing basal cell tumours in the dog and cat. J Small Anim Pract 2001; 42 (12): 582-586
  • 37 Strafuss AC. Basal cell tumors in dogs. J Am Vet Med Assoc 1976; 169 (3): 322-324
  • 38 Thomson MJ, Withrow SJ, Dernell WS. et al. Intermuscular lipomas of the thigh region in dogs: 11 cases. J Am Anim Hosp Assoc 1999; 35 (2): 165-157
  • 39 Ward H, Fox LE, Calderwood-Mays MB. et al. Cutaneous hemangiosarcoma in 25 dogs: a retrospective study. J Vet Intern Med 1994; 8 (5): 345-348
  • 40 Warland J, Amores-Fuster I, Newbury W. et al. The utility of staging in canine mast cell tumours. Vet Comp Oncol 2014; 12 (4): 287-298
  • 41 Warland J, Dobson J. Breed predispositions in canine mast cell tumour: a single centre experience in the United Kingdom. Vet J 2013; 197 (2): 496-498
  • 42 Weiss E, Frese K. Tumours of the skin. Bull World Health Organ 1974; 50 (1–2): 79-100
  • 43 Wright ZM, Rogers KS, Mansell J. Survival data for canine oral extramedullary plasmacytomas: a retrospective analysis (1996–2006). J Am Anim Hosp Assoc 2008; 44 (2): 75-81